Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups. Issue 12 (10th August 2015)
- Record Type:
- Journal Article
- Title:
- Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups. Issue 12 (10th August 2015)
- Main Title:
- Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups
- Authors:
- Oberlin, Odile
Rey, Annie
Brown, Kenneth L.B.
Bisogno, Gianni
Koscielniak, Ewa
Stevens, Michael C.G.
Hawkins, Douglas S.
Meyer, William H.
La, Trang H.
Carli, Modesto
Anderson, James R. - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25684-sec-0001" sec-type="section"> <title>Background</title> <p>Extremity rhabdomyosarcomas do not always show satisfactory outcomes. We analyzed data from 643 patients treated in 14 studies conducted by European and North American groups between 1983 and 2004 to identify factors predictive of outcome.</p> </sec> <sec id="pbc25684-sec-0002" sec-type="section"> <title>Procedure</title> <p>Clinical factors, including age; histology; site of primary (hand and foot vs. other); size; invasiveness (T stage); nodal involvement (N stage); and treatment factors, including post‐surgical group; chemotherapy type and duration; radiotherapy; and treatment (before or after 1995); were evaluated for impact on overall survival (OS).</p> </sec> <sec id="pbc25684-sec-0003" sec-type="section"> <title>Results</title> <p>5‐year OS were 67% (se 1.8). Multivariate analysis showed that lower OS correlated with age &gt;3 years, T2 and N1 stage, incomplete initial surgery, treatment before 1995, and European cooperative group treatment. Patients with gross residual disease after initial incomplete resection/biopsy had similar outcomes in both continental groups. The better global survival of patients treated in American studies was accounted for by differences in outcome in the subset of those with grossly resected tumors (OS 86% [se 3] for COG patients vs. 68% [se 4] for European patients<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25684-sec-0001" sec-type="section"> <title>Background</title> <p>Extremity rhabdomyosarcomas do not always show satisfactory outcomes. We analyzed data from 643 patients treated in 14 studies conducted by European and North American groups between 1983 and 2004 to identify factors predictive of outcome.</p> </sec> <sec id="pbc25684-sec-0002" sec-type="section"> <title>Procedure</title> <p>Clinical factors, including age; histology; site of primary (hand and foot vs. other); size; invasiveness (T stage); nodal involvement (N stage); and treatment factors, including post‐surgical group; chemotherapy type and duration; radiotherapy; and treatment (before or after 1995); were evaluated for impact on overall survival (OS).</p> </sec> <sec id="pbc25684-sec-0003" sec-type="section"> <title>Results</title> <p>5‐year OS were 67% (se 1.8). Multivariate analysis showed that lower OS correlated with age &gt;3 years, T2 and N1 stage, incomplete initial surgery, treatment before 1995, and European cooperative group treatment. Patients with gross residual disease after initial incomplete resection/biopsy had similar outcomes in both continental groups. The better global survival of patients treated in American studies was accounted for by differences in outcome in the subset of those with grossly resected tumors (OS 86% [se 3] for COG patients vs. 68% [se 4] for European patients (<italic>P</italic> = 0.004)). When excluding chemotherapy duration from the model, analysis in this subset of patients showed that cooperative group (<italic>P</italic> = 0.001), site (<italic>P</italic> = 0.001), and T stage (<italic>P</italic> = 0.05) were all significant. However, after adding duration of chemotherapy (≥27 weeks) to the model, only primary site remained significant (<italic>P</italic> = 0.006).</p> </sec> <sec id="pbc25684-sec-0004" sec-type="section"> <title>Conclusion</title> <p>This meta‐analysis confirms the role of many established prognostic factors but identifies for the first time that chemotherapy duration may have an impact on outcome in patients with grossly resected tumors. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Pediatric blood & cancer. Volume 62:Issue 12(2015:Dec.)
- Journal:
- Pediatric blood & cancer
- Issue:
- Volume 62:Issue 12(2015:Dec.)
- Issue Display:
- Volume 62, Issue 12 (2015)
- Year:
- 2015
- Volume:
- 62
- Issue:
- 12
- Issue Sort Value:
- 2015-0062-0012-0000
- Page Start:
- 2125
- Page End:
- 2131
- Publication Date:
- 2015-08-10
- Subjects:
- Tumors in children -- Periodicals
Blood -- Diseases -- Periodicals
Cancer in children -- Periodicals
618.92 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/pbc.25684 ↗
- Languages:
- English
- ISSNs:
- 1545-5009
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6417.533500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3996.xml